Overview

Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder

Status:
Active, not recruiting

Trial end date:
2021-10-31

Target enrollment:

Participant gender:

Summary

A clinical study to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone therapy compared to placebo for the treatment of seizures in children and young adults with genetically confirmed CDKL5 gene mutation.

Phase:

Phase 3

Details

Lead Sponsor:

Marinus Pharmaceuticals

Treatments:

Ganaxolone
Pregnanolone